Obesity Drug Reprograms Fat & Energy Use – Scientists Reveal
- * What: RES-010,a new drug developed by Resalis Therapeutics,aims to treat the underlying causes of obesity by targeting miR-22,a key regulator of metabolism.
- Drugs like semaglutide, a GLP-1 receptor agonist, have revolutionized obesity treatment by reducing appetite, slowing gastric emptying, and increasing feelings of fullness.
- Resalis Therapeutics is taking a different tack with RES-010, an antisense oligonucleotide.Antisense oligonucleotides are short,synthetically produced fragments of genetic material designed to block specific RNA molecules within the...
RES-010: A Novel Approach to obesity Treatment Targeting Metabolic Reprogramming
Table of Contents
At-a-Glance:
* What: RES-010,a new drug developed by Resalis Therapeutics,aims to treat the underlying causes of obesity by targeting miR-22,a key regulator of metabolism.
* How: It’s an antisense oligonucleotide administered weekly via subcutaneous injection, designed to reprogram metabolism rather than simply suppress appetite.
* Where: Research presented at the European Association for the Study of Diabetes (EASD) annual meeting in Vienna, austria (September 15-19).
* Why it Matters: Current obesity treatments like GLP-1 agonists (e.g.,semaglutide) are effective for weight loss,but weight regain is common after stopping treatment. RES-010 aims for more durable results by addressing the root metabolic issues.
* What’s next: A Phase 1 clinical trial is currently underway.
Obesity is a complex health issue, and while recent advancements in treatments like GLP-1 receptor agonists have shown promise, a critically important challenge remains: weight regain after treatment cessation. A new drug, RES-010, presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in vienna, Austria, offers a potentially groundbreaking approach by targeting the underlying causes of obesity, rather than just its symptoms.
The Limitations of Current Obesity Treatments
Drugs like semaglutide, a GLP-1 receptor agonist, have revolutionized obesity treatment by reducing appetite, slowing gastric emptying, and increasing feelings of fullness. However, these drugs don’t address the fundamental metabolic disruptions that drive obesity. As Riccardo Panella, co-founder and CEO of Resalis Therapeutics, explains, obesity is driven by more than just appetite; it involves disrupted lipid and glucose metabolism, changes in adipose tissue, and mitochondrial dysfunction. This leaves a significant possibility for new therapeutic strategies.
Introducing RES-010: targeting miR-22 for Metabolic Reprogramming
Resalis Therapeutics is taking a different tack with RES-010, an antisense oligonucleotide.Antisense oligonucleotides are short,synthetically produced fragments of genetic material designed to block specific RNA molecules within the body. RES-010 specifically targets miR-22, a molecule Dr. Panella describes as a “master controller” of several processes crucial to obesity.
what does miR-22 control?
* Lipid Metabolism: How the body breaks down and utilizes fats.
* Mitochondrial Function: The production and activity of mitochondria, the powerhouses of cells.
* Adipose Tissue Remodeling: changes in the organization and function of body fat.
By blocking miR-22, RES-010 aims to concurrently address these interconnected metabolic factors, effectively “reprogramming” the metabolism for long-lasting weight loss.
Promising Pre-Clinical Results
Pre-clinical studies have yielded encouraging results. In tests conducted on obese mice, those receiving weekly injections of RES-010 experienced approximately 12% more weight loss compared to untreated mice. Crucially, this weight loss occurred gradually over five months, leading the animals to achieve a healthy weight.
Key Finding: The treated mice lost weight despite consuming the same amount of food as the untreated mice. This suggests that RES-010 isn’t simply suppressing appetite, but rather fundamentally altering how the body processes and utilizes energy.
“Importantly,the treated mice lost weight despite eating the same amount as the untreated mice,which suggests RES-010 isn’t suppressing appetite but reprogramming the metabolism.” - Riccardo Panella
What’s Next: Phase 1 Clinical Trial
Following the positive pre-clinical data, a Phase 1 clinical trial is now underway to assess the safety and tolerability of RES-010 in humans. This initial trial will pave the way for larger studies to evaluate the drug’s efficacy in achieving sustained weight loss and improving metabolic health.
Editor’s Analysis – Dr. Jennifer Chen
The approach taken by Resalis Therapeutics with RES-010 is a compelling one. While GLP-1 agonists have been a game-changer for many, the issue of weight regain highlights the need for therapies that address the underlying pathophysiology of obesity. Targeting miR-22,a central regulator of multiple metabolic pathways,offers a potentially more durable solution. The pre-clinical data are especially encouraging, demonstrating weight loss without caloric restriction, which suggests a true metabolic shift. Though, it’s crucial to remember that results in mice don’t always translate to humans. The Phase 1 trial will be